Feasibility and availability of 68Ga-labelled peptides
- 897 Downloads
68Ga has attracted tremendous interest as a radionuclide for PET based on its suitable half-life of 68 min, high positron emission yield and ready availability from 68Ge/68Ga generators, making it independent of cyclotron production. 68Ga-labelled DOTA-conjugated somatostatin analogues, including DOTA-TOC, DOTA-TATE and DOTA-NOC, have driven the development of technologies to provide such radiopharmaceuticals for clinical applications mainly in the diagnosis of somatostatin receptor-expressing tumours. We summarize the issues determining the feasibility and availability of 68Ga-labelled peptides, including generator technology, 68Ga generator eluate postprocessing methods, radiolabelling, automation and peptide developments, and also quality assurance and regulatory aspects. 68Ge/68Ga generators based on SnO2, TiO2 or organic matrices are today routinely supplied to nuclear medicine departments, and a variety of automated systems for postprocessing and radiolabelling have been developed. New developments include improved chelators for 68Ga that could open new ways to utilize this technology. Challenges and limitations in the on-site preparation and use of 68Ga-labelled peptides outside the marketing authorization track are also discussed.
Keywords68Ga 68Ge/68Ga generator Radiolabelled peptides Postprocessing Automated synthesis
The assistance of Dr B.J. McParland with dosimetry calculations is acknowledged
Conflict of interest
The authors declare that they have no conflict of interest.
- 7.Meinken GE, Kurczak SM, Kolsky KL, Srivastava SC. Production of high specific activity 68Ge at Brookhaven National laboratory. J Radioanal Nucl Chem. 2005;263:553–7.Google Scholar
- 15.Razbash AA. A simple gallium-68 generator. Eur J Nucl Med Mol Imaging. 2003;30 Suppl 2:S318.Google Scholar
- 19.Zhernosekov K, Harfensteller M, Moreno J, Leib O, Buck O, Tuerler A, et al. Development of a novel metal-free 68Ge/68Ga radionuclide generator system. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 2:S251.Google Scholar
- 22.Loktionova NS, Rösch F. Separation of 68Ga and 68Ge on TLC plate. World J Nucl Med. 2011;10:80Google Scholar
- 23.ICRP. Limits for Intakes of Radionuclides by Workers. ICRP Publication 30 (Part 3). Ann ICRP. 6 (2-3).Google Scholar
- 24.Konijnenberg M, Breeman WA (2009) Estimates for the biodistribution and dosimetry of 68Ge in 68Ga PET imaging. J Lab Comp Radiopharm 52 Suppl 1:S116.Google Scholar
- 30.US Food and Drug Administration. FDA Drug Safety Communication: Increased radiation exposure due to undetected strontium breakthrough when using CardioGen-82 for cardiac positron emission tomography (PET) scans. US Food and Drug Administration; 2011. http://www.fda.gov/Drugs/DrugSafety/ucm263112.htm. Accessed 19 Nov 2011.
- 35.Müller D, Klette I, Baum RP. A new high efficient NaCl base cationic 68Ge/68Ga generator eluate purification. World J Nucl Med. 2011;10:77.Google Scholar
- 48.European Directorate for the Quality of Medicines. Gallium (68Ga) edotreotide injection. Pharmeuropa. 2011;23:310–2.Google Scholar
- 49.Hesselmann R, Johayem A, Özdemir U, Dragic M, Blainc A, Mu L, et al. Improving radiochemical purity and quality control of 68Ga-DOTATATE. World J Nucl Med. 2011;10:84.Google Scholar
- 52.The European Parliament and of the Council of the European Union. Directive 2004/27/EC of the European Parliament and the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal. L136;2004:34–57.Google Scholar
- 55.EudraLex. The rules governing medicinal products in the European Union. Volume 4: EU guidelines to good manufacturing practice medicinal products for human and veterinary use. Part II: basic requirements for active substances used as starting materials. http://ec.europa.eu/health/files/eudralex/vol-4/2007_09_gmp_part2_en.pdf 2005.